VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VIVS
VivoSim Labs, Inc. (VIVS) Altman Z-score
VivoSim Labs, Inc.'s Altman Z-score for fiscal 2026 is −71.71, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −71.71 | (37.34) |
| FY2025 | −34.37 | 45.91 |
| FY2024 | −80.27 | (58.10) |
| FY2023 | −22.18 | (15.52) |
| FY2022 | −6.66 | (9.21) |
| FY2020 | 2.55 | (3.20) |
| FY2019 | 5.74 | 0.91 |
| FY2018 | 4.83 | (17.73) |
| FY2017 | 22.56 | 4.98 |
| FY2016 | 17.58 | (13.68) |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.52 | — | 0.62 | |
| Retained earnings / total assets | (48.20) | — | −67.48 | |
| EBIT / total assets | (1.56) | — | −5.13 | |
| Market value of equity / total liabilities | 0.44 | — | 0.26 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −71.71 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −164.30 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| DCOY Decoy Therapeutics Inc compare | 4.3× |
| HCWB HCW Biologics Inc. compare | −8.8× |
| ONCO Onconetix, Inc. compare | −9.8× |
| AFMDQ Affimed N.V. compare | −10.4× |
| BCAB BioAtla, Inc. compare | −70.1× |
| VIVS VivoSim Labs, Inc. | −71.7× |
| SLXN Silexion Therapeutics Corp compare | — |
| MBIO Mustang Bio, Inc. compare | — |
| ARAV ARAVIVE, INC compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets